Publications found:
253,840
Sort by:
Market Access Impact (EU5) [CLL]
US$ 5,145.00
... or changed? Market Access Impact: CLL (EU5) examines the dynamics of the CLL drug market in Europe. It specifically looks at how various market access barriers are impacting the 5 most popular CLL drugs from ... on Market Access issues Market Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You’ll learn: How barriers affect market access Which CLL ...
May 2017
Market Access Impact (EU5) [Growth Hormone Deficiency]
US$ 5,145.00
... bigger problem Market barriers affect nearly 25% of growth hormone prescriptions in the EU5 countries. Most brands lose market share because of ... Market Access Barriers Market Access Impact: GHD (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What ...
May 2017
Market Access Impact (EU5) [Haemophilia A]
US$ 5,145.00
... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A (EU5). Based on a survey ... alfa; Pfizer) Exploring Market Access Barriers Market Access Impact: Haemophilia A (EU5) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...
May 2017
Market Access Impact (US) [CLL]
US$ 5,145.00
... or changed? Market Access Impact: CLL (US) examines the dynamics of the CLL drug market in the US. It specifically looks at how various market access barriers are impacting the 6 most popular CLL drugs from ... on Market Access issues Market Access Impact: CLL provides an up-to-date assessment of the issues affecting current prescribing patterns for CLL drugs. You’ll learn: How barriers affect market access Which CLL ...
May 2017
Market Access Impact (US) [Growth Hormone Deficiency]
US$ 5,145.00
... than one thing Market barriers affect over 20% of growth hormone prescriptions in the US, and most brands lose market share because of ... Exploring Market Access Barriers Market Access Impact: GHD (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access What brands ...
May 2017
Market Access Impact (US) [Haemophilia A]
US$ 5,145.00
... 7 barriers affect your market share, see who you take share from, and who gets your lost share in Market Access Impact: Haemophilia A (US). Based on a survey ... alfa; Pfizer Exploring Market Access Barriers Market Access Impact: Haemophilia A (US) explores key issues affecting drug manufacturers. You’ll learn: How barriers affect market access: What brands do doctors ...
May 2017
Medical Affairs in Orphan Drugs
US$ 695.00
... awareness considerably The role of medical affairs in orphan drug development and commercialisation Summary The medical affairs team tends to play a pivotal role in orphan drug R&D Medical affairs has a critical role in identifying ... in resources for medical affairs highlights its importance for orphan drugs A different approach to non-orphan indications is required The future for medical affairs in orphan drugs Summary Medical affairs will continue to play ...
May 2017
Medical Affairs Reputations (EU5) [MS]
US$ 6,175.00
... report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS EU5) features 10 leading MS drugs from ... (natalizumab; Biogen) A Competitive Assessment of Medical Affairs Teams Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions ...
May 2017
Medical Affairs Reputations (US) [MS]
US$ 6,175.00
... report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS (US) features 11 leading MS drugs from ... ; AbbVie/Biogen) A Competitive Assessment of Medical Affairs Teams Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions ...
May 2017
NASH: KOL Insight [2017]
US$ 8,795.00
... how KOLs see the market evolving, and how they expect developers to differentiate their pipeline therapies in KOL Insight: Nonalcoholic steatohepatitis (NASH). 6 US and 6 European KOLs give their insight on two off-label marketed products and 12 pipeline programmes. KOLs also provide ...
May 2017
NPS+ (EU5) [Melanoma]
US$ 2,575.00
... from competitors in FirstView’s NPS+ Melanoma 2017 (EU5). Building on the respected net promoter score (NPS), the report compares seven major melanoma drugs with easy ... and 9th, 2017. Explore Important Brand Loyalty Issues NPS+ Melanoma 2017 (EU5) explores key issues affecting brand loyalty for drug manufacturers ...
May 2017
NPS+ (US) [Melanoma]
US$ 2,575.00
... satisfaction score in FirstView’s NPS+ Melanoma 2017 (US). Building on the respected net promoter score (NPS), the report compares eight major melanoma drugs with easy ... 3rd and 9th, 2017. Explore Important Brand Loyalty Issues NPS+ Melanoma 2017 (US) explores key issues affecting brand loyalty for drug ...
May 2017
The United States Digital Medicine Market (2017-2021 Edition)
US$ 600.00
... report titled “The United States Digital Medicine Market (2017-2021 Edition)”, provides an in-depth analysis of the scenario of digital medicine market in the United States. The US digital medicine market has been analysed on the basis of value, segments and clinical trials sponsors. The report also provides the digital ...
May 2017
34 pages
Acute Respiratory Distress Syndrome (ARDS) Forecast in 11 Major Markets 2017-2027
US$ 6,150.00
Acute respiratory distress syndrome (ARDS) is an acute severe lung disease. It most often develops in those admitted to an intensive ... in protein-rich non-cardiogenic pulmonary oedema, refractory hypoxaemia and acute respiratory failure. This report provides the current prevalent population for ...
May 2017
42 pages
PD-L1 Overexpression in Solid Tumours Forecast in 18 Major Markets 2017-2027
US$ 6,150.00
PD-1 is a T-cell immune checkpoint that is involved in the dampening of autoimmunity in the peripheral effector phase of T-cell activation. This leads to a ‘tolerance’ of cells expressing PD-L1 (programmed death ligand-1). PD-L1 is expressed normally on a number of different cell types including; placenta, ...
May 2017
148 pages
AML [2017]: Bulletin #1
US$ 1,045.00
This update bulletin presents key opinion leader (KOL) views on recent developments in the acute myeloid leukaemia (AML) market. Topics covered include ... enasidenib (AG-221) for the treatment of patients with relapsed/refractory AML with an isocitrate dehydrogenase 2 (IDH2) mutation. Business Questions How do KOLs ...
May 2017
CLL [2016]: Bulletin #3
US$ 1,045.00
... provide their candid insights on the sequencing of novel targeted therapies in CLL, availability of real-world data and the future of chemotherapies. Business ... KOLs require clinical studies to demonstrate the similarity of Truxima to rituximab in CLL? If so, what studies are required? How comfortable are KOLs in extrapolating ...
May 2017
Cystic Fibrosis [2017]: Bulletin #1
US$ 1,045.00
... presents key opinion leader (KOL) views on recent developments in the cystic fibrosis market. Topics covered include: Corbus Pharmaceuticals’s announcement of positive data ...
May 2017
Hepatitis C [2016]: Bulletin #3
US$ 1,045.00
... presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating ...
May 2017
HNSCC [2017]: Bulletin #1
US$ 1,045.00
... (HNSCC). Topics covered include: KOL views on the approval of Bristol Myers Squibb’s Opdivo (nivolumab) for the second-line treatment of HNSCC, in April 2017 ... cancers, including HNSCC. Business Questions In March 2017, the EU’s CHMP recommended approval of Bristol-Myers Squibb’s Opdivo for the treatment of HNSCC, but how ...
May 2017
Melanoma [2016]: Bulletin #2
US$ 1,045.00
... of its investigational intratumoral therapy, ImmunoPulse IL-12, with Keytruda (pembrolizumab) in metastatic melanoma patients who are not expected to respond to anti-PD-1 agents. Business ... NDA for binimetinib as monotherapy in NRAS melanoma the right one? Does binimetinib have a future in NRAS melanoma? Is there room for the market ...
May 2017
Multiple Sclerosis [2016]: Bulletin #2
US$ 1,045.00
... events that have the potential to impact the treatment landscape of multiple sclerosis (MS). Topics covered include expert opinions on: the FDA approval of Ocrevus ...
May 2017
NSCLC [2016]: Bulletin #3
US$ 1,045.00
... on the latest events happening in non-small cell lung cancer (NSCLC), including: the EU approval of Novartis’s Mekinist (trametinib) in combination with Tafinlar ... in the first-line treatment of ALK-positive NSCLC? How is the second-line treatment of ALK-positive NSCLC likely to evolve in light of recent events ...
May 2017
Payer Insights: RA [2016]: Bulletin #2
US$ 1,045.00
... ’s Olumiant (baricitinib) gaining marketing authorisation in the EU. Business Questions How do payers intend to cover sarilumab? Will there be any restrictions? Is sarilumab likely ... over biosimilars of Humira? How are biosimilars of Remicade viewed by payers? Are payers surprised that baricitinib was declined approval in the US, but not ...
May 2017
Global Preclinical Tomography System Market by Manufacturers, Countries, Type and Application, Forecast to 2022
US$ 3,480.00
... display the global Preclinical Tomography System market. Chapter 1, to describe Preclinical Tomography System Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Preclinical Tomography System, with ...
May 2017
120 pages
Global Robotic Surgery Market: Industry Analysis & Outlook (2017-2021)
US$ 800.00
... of robot in general surgery. However, the expansion of the market is hindered by risks of robotic surgery and challenges of laparoscope control. The report “Global Robotic Surgery Market” provides a comprehensive study of the global market for ...
May 2017
70 pages
Global Orphan Drugs Market- Industry Analysis & Outlook (2017-2021)
US$ 800.00
... improving healthcare facilities. The global orphan drugs market is expected to grow in future due to prolonged orphan drug market exclusivity, increasing sales of prescription drugs, attractive orphan drug policies, rising healthcare expenditure ...
May 2017
67 pages
Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)
US$ 800.00
... are being developed, which are in their clinical phases. The global Rett syndrome market will grow over the years driven by increase in female ... like high cost of treatment and high R&D expenditure. The report “Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)” analyzes the development of ...
May 2017
64 pages
Biostimulants - Global Market Outlook (2017-2023)
US$ 4,150.00
... the Global Biostimulants Market is accounted for $1.50 billion in 2016 and expected to grow at a CAGR of 14.1% to reach $3.79 billion by 2023. The market is expected to ... agricultural practices. Some of the key players in Global Biostimulants Market are Agrinos AS, Atlantica Agricola, Biostadt India Ltd, Brandt ...
May 2017
168 pages
Prostate Cancer Therapeutics - Global Market Outlook (2017-2023)
US$ 4,150.00
... Prostate Cancer Therapeutics market is estimated at $XX million in 2016 and is expected to reach $XX million by 2023 growing at a CAGR of XX% from 2016 to 2023. Increase in prostate cancer ... period because of government initiatives on creating awareness on prostate cancer. Some of the key players in the market ...
May 2017
148 pages
Vitamin D Testing - Global Market Outlook (2017-2023)
US$ 4,150.00
According to Stratistics MRC, the Global Vitamin D Testing Market is expected to grow at a CAGR of 6.2% during the forecast period. ... region. Some of the key players in Vitamin D Testing market include F. Hoffmann-La Roche Ltd., Abbott Diagnostics, Vitamin D Company, Siemens Healthcare Diagnostics, Biomeriux ...
May 2017
158 pages
ASIA-PACIFIC OPHTHALMIC DRUGS & DEVICES MARKET FORECAST 2017-2025
US$ 1,250.00
KEY FINDINGS Asia Pacific ophthalmic drugs & devices market was valued at $11815.02 million in 2016 and ... the high dominance of refractive errors. MARKET INSIGHTS The Asia-Pacific ophthalmic drugs & devices market is segmented by ophthalmic devices, surgery devices, vision care, by type of diseases, by ...
May 2017
78 pages
EUROPE ORTHOPEDIC MARKET FORECAST 2017-2024
US$ 1,250.00
KEY FINDINGS The Europe orthopedic market is anticipated to grow $21966 million by 2024. The market growth is expected at the CAGR of 5.94% in the forecast period. The base year considered for ...
May 2017
81 pages
EUROPE STEM CELL ASSAY MARKET FORECAST 2017-2025
US$ 1,250.00
... . The Europe stem cell assay market by type is segmented into cell viability and toxicity assays, isolation and purification assays, cell identification assays, cell differentiation assays, cell function assays and cell apoptosis assays. The product of Europe stem cell assay market is segmented ...
May 2017
59 pages
Global Ophthalmic Drugs Market Forecast 2017-2024
US$ 2,500.00
... North America ophthalmic drugs & devices market holds high growth prospects in the near futureHowever, over the forecasted period Asia- ... , this market is dominated by global players like Alex and Topcon Corporation.Global ophthalmic drugs market has a large number of market players but, the market is dominated ...
May 2017
172 pages
NORTH AMERICA ORTHOPEDIC MARKET FORECAST 2017-2024
US$ 1,250.00
... the growth of the orthopedic market in the region. MARKET INSIGHTS The North America orthopedic market is segmented on the basis of procedure, ortho biologics, and geography. The North America orthopedic market by the procedure ...
May 2017
85 pages
NORTH AMERICA STEM CELL ASSAY MARKET FORECAST 2017-2025
US$ 1,250.00
... North America stem cell assay market by type is segmented into cell viability and toxicity assays, isolation and purification assays, cell identification assays, cell differentiation assays, cell function assays and cell apoptosis assays. The product of North America stem cell assay market ...
May 2017
62 pages
North America Surgical Sealants and Adhesives Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
US$ 4,200.00
... 2024. Based on geography, the North America Surgical Sealants and Adhesives market is segmented into 11 geographical regions, such as, Japan, North America, South America, Europe, Asia-Pacific, Middle ...
May 2017
150 pages
Oxygen Therapy Equipment Market by Product (Oxygen Source (Concentrator, Cylinder), Delivery Devices), Portability (Stationary, Portable), Application (COPD, Asthma, Cystic Fibrosis, Pneumonia), End User (Hospital, Home Care) - Global Forecast to 2022
US$ 5,650.00
... oxygen therapy in the U.S. Oxygen source equipment to register the highest CAGR during the forecast period The oxygen therapy equipment market is classified on the basis of products into oxygen source equipment and oxygen ... players in the oxygen therapy equipment market Market Development: Comprehensive information about emerging markets. This report analyses the market for various oxygen therapy products across geographies Market Diversification: Exhaustive ...
May 2017
177 pages
Vitamin D Testing Market Analysis By Type of Test (25-Hydroxy Vitamin D Tests; 1, 25-Dihydroxy Vitamin D Tests), Region (North America, Europe, Asia Pacific, South & Central America, MEA), And Segment Forecasts, 2014 - 2025
US$ 5,950.00
The global vitamin D testing market is expected to reach USD 1.1 billion by 2025, according to a new report by ... level of vitamin D in two forms. Hence, the market has been divided by two major types of tests, namely 25-Hydroxy Vitamin D test and 1, 25-Dihydroxy vitamin test. The 5-hydroxy vitamin D tests or ...
May 2017
100 pages
Global Medicated Skin Care Products Industry Market Research 2017
US$ 2,600.00
... driving the global Medicated Skin Care Products industry? 8. What are the key market trends impacting the growth of the Medicated Skin Care Products market? 9. What are the Medicated Skin Care Products market challenges to market growth? 10. What are the Medicated Skin Care Products market opportunities and threats faced by the vendors in the global Medicated Skin Care Products market ...
May 2017
157 pages
Fressnapf Hungária Kft in Pet Care (Hungary)
US$ 150.00
Fressnapf Hungária Kft will dominate Hungarian pet food specialist retailing with a focus on Budapest and the largest ... through this collection of snapshot company profiles. Product coverage: Pet Food, Pet Products. Data coverage: market sizes (historic and forecasts), company ...
May 2017
3 pages
Nestlé Hungária Kft in Pet Care (Hungary)
US$ 150.00
Nestlé Hungária Kft will maintain its leadership in dog food and cat food ... through this collection of snapshot company profiles. Product coverage: Pet Food, Pet Products. Data coverage: market sizes (historic and forecasts), company ...
May 2017
2 pages
